VIVS
VivoSim Labs, Inc.
Price Chart
Latest Quote
$1.17
-0.03 (-2.09%)
Current Price
| Previous Close | $1.20 |
| Open | $1.19 |
| Day High | $1.21 |
| Day Low | $1.15 |
| Volume | 58,551 |
Stock Information
| Shares Outstanding | 2.89M |
| Total Debt | $812K |
| Cash Equivalents | $4.29M |
| Revenue | $142K |
| Net Income | $-1.23M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $3.39M |
| P/E Ratio | 0.66 |
| EPS (TTM) | $1.76 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-425K |
| Sales | $142K |
| Income | $-1.23M |
| Book/sh | $1.70 |
| Cash/sh | $1.48 |
| Employees | 14 |
Financial Ratios
| Quick Ratio | 1.75 |
| Current Ratio | 2.44 |
| Debt/Eq | 18.28 |
Returns & Margins
| ROA | -132.52% |
| ROE | -51.07% |
| Operating Margin | -10576.92% |
Ownership
| Insider Ownership | 14.80% |
| Institutional Ownership | 7.69% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/S | 23.85 |
| P/B | 0.69 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $nan |
| SMA50 | $nan |
| SMA200 | $nan |
| RSI | 40.91 |
| ATR | nan |
| Shares Float | 2.33M |
| Short Float | 1.16% |
| Short Ratio | 0.79 |
| Volatility | 1.38 |
| Rel Volume | 1.00 |
Performance History
| Week | nan% |
| Month | nan% |
| Quarter | nan% |
| 6 Months | nan% |
| YTD | nan% |
| Year | nan% |
| 3 Years | nan% |
| 5 Years | nan% |
| 10 Years | nan% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-16 | $nan | 58,551 |
| 2026-06-15 | $1.21 | 66,400 |
| 2026-06-12 | $1.14 | 34,300 |
| 2026-06-11 | $1.16 | 23,900 |
| 2026-06-10 | $1.18 | 15,500 |
| 2026-06-09 | $1.19 | 38,800 |
| 2026-06-08 | $1.19 | 23,800 |
| 2026-06-05 | $1.20 | 201,200 |
| 2026-06-04 | $1.35 | 115,400 |
| 2026-06-03 | $1.26 | 34,900 |
| 2026-06-02 | $1.28 | 31,900 |
| 2026-06-01 | $1.29 | 63,500 |
| 2026-05-29 | $1.31 | 59,500 |
| 2026-05-28 | $1.31 | 25,500 |
| 2026-05-27 | $1.29 | 20,200 |
| 2026-05-26 | $1.29 | 30,000 |
| 2026-05-22 | $1.36 | 37,200 |
| 2026-05-21 | $1.34 | 248,900 |
| 2026-05-20 | $1.30 | 26,100 |
| 2026-05-19 | $1.29 | 18,500 |
| 2026-05-18 | $1.27 | 13,500 |
About VivoSim Labs, Inc.
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
đ° Latest News
NIO January Deliveries Nearly Double Year On Year
GuruFocus.com âĸ 2026-02-02T11:59:48ZTop Midday Gainers
MT Newswires âĸ 2026-01-30T18:48:11ZBC-Most Active Stocks
Associated Press Finance âĸ 2026-01-30T15:30:19ZWall Street Set to Open Lower Friday as Investors React to Trump's Choice of Warsh as Fed Chair
MT Newswires âĸ 2026-01-30T14:14:21ZRivian vs. NIO: Which EV Manufacturer Stock Is Worth Buying?
Zacks âĸ 2026-01-28T15:40:00Z
Did Record 2025 Deliveries and a MultiâBrand EV Push Just Shift NIO's (NIO) Investment Narrative?
Simply Wall St. âĸ 2026-01-05T22:11:56Z
The Zacks Analyst Blog NIO, XPeng and Li Auto
Zacks âĸ 2026-01-05T13:36:00Z
NIO, XPeng & Li Auto Report December & Fourth-Quarter Delivery Results
Zacks âĸ 2026-01-02T15:41:00Z
NIO Posts Record December and Q4 Deliveries as 2025 Volumes Surge
GuruFocus.com âĸ 2026-01-02T12:03:16Z
How Investors Are Reacting To NIO (NIO) Surging November Deliveries Across Its MultiâBrand EV Lineup
Simply Wall St. âĸ 2025-12-13T19:06:58Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $5,000 | $0 | - | - |
| Cost Of Revenue | $5,000 | $0 | - | - |
| Total Revenue | $144,000 | $109,000 | $370,000 | $1,500,000 |
| Operating Revenue | $144,000 | $109,000 | $370,000 | $1,500,000 |
| Expenses | ||||
| Interest Expense | $10,000 | $0 | - | - |
| Total Expenses | $12,760,000 | $15,195,000 | $18,101,000 | $12,979,000 |
| Other Income Expense | $10,000,000 | $12,000 | $20,000 | $25,000 |
| Net Non Operating Interest Income Expense | $130,000 | $405,000 | $454,000 | $8,000 |
| Interest Expense Non Operating | $10,000 | $0 | - | - |
| Operating Expense | $12,755,000 | $15,195,000 | $18,101,000 | $12,979,000 |
| General And Administrative Expense | $7,691,000 | $9,644,000 | $9,088,000 | $9,631,000 |
| Other Non Operating Income Expenses | - | - | - | $25,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-2,488,000 | $-14,671,000 | $-17,259,000 | $-11,448,000 |
| Net Interest Income | $130,000 | $405,000 | $454,000 | $8,000 |
| Interest Income | $140,000 | $405,000 | $454,000 | $8,000 |
| Normalized Income | $-10,388,000 | $-14,683,000 | $-17,279,000 | $-11,448,000 |
| Net Income From Continuing And Discontinued Operation | $-2,488,000 | $-14,671,000 | $-17,259,000 | $-11,448,000 |
| Total Operating Income As Reported | $-12,616,000 | $-15,086,000 | $-17,731,000 | $-11,479,000 |
| Net Income Common Stockholders | $-2,488,000 | $-14,671,000 | $-17,259,000 | $-11,448,000 |
| Net Income | $-2,488,000 | $-14,671,000 | $-17,259,000 | $-11,448,000 |
| Net Income Including Noncontrolling Interests | $-2,488,000 | $-14,671,000 | $-17,259,000 | $-11,448,000 |
| Net Income Continuous Operations | $-2,488,000 | $-14,671,000 | $-17,259,000 | $-11,448,000 |
| Pretax Income | $-2,486,000 | $-14,669,000 | $-17,257,000 | $-11,446,000 |
| Special Income Charges | $10,000,000 | $0 | $-9,000 | $0 |
| Interest Income Non Operating | $140,000 | $405,000 | $454,000 | $8,000 |
| Operating Income | $-12,616,000 | $-15,086,000 | $-17,731,000 | $-11,479,000 |
| Depreciation Amortization Depletion Income Statement | $39,000 | $53,000 | $128,000 | $28,000 |
| Depreciation And Amortization In Income Statement | $39,000 | $53,000 | $128,000 | $28,000 |
| Gross Profit | $139,000 | $109,000 | - | - |
| Per Share | ||||
| Diluted EPS | $-1.70 | $-19.25 | $-23.76 | $-15.84 |
| Basic EPS | $-1.70 | $-19.25 | $-23.76 | $-15.84 |
| Other | ||||
| Tax Effect Of Unusual Items | $2,100,000 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-12,210,000 | $-14,401,000 | $-17,458,000 | $-11,337,000 |
| Total Unusual Items | $10,000,000 | $12,000 | $20,000 | $0 |
| Total Unusual Items Excluding Goodwill | $10,000,000 | $12,000 | $20,000 | $0 |
| Reconciled Depreciation | $266,000 | $280,000 | $293,000 | $142,000 |
| EBITDA (Bullshit earnings) | $-2,210,000 | $-14,389,000 | $-17,438,000 | $-11,337,000 |
| EBIT | $-2,476,000 | $-14,669,000 | $-17,731,000 | $-11,479,000 |
| Diluted Average Shares | $1,463,609 | $762,076 | $726,085 | $725,299 |
| Basic Average Shares | $1,463,609 | $762,076 | $726,085 | $725,299 |
| Diluted NI Availto Com Stockholders | $-2,488,000 | $-14,671,000 | $-17,259,000 | $-11,448,000 |
| Tax Provision | $2,000 | $2,000 | $2,000 | $2,000 |
| Gain On Sale Of Ppe | $10,000,000 | $0 | $-9,000 | $0 |
| Research And Development | $5,025,000 | $5,498,000 | $8,885,000 | $3,320,000 |
| Selling General And Administration | $7,691,000 | $9,644,000 | $9,088,000 | $9,631,000 |
| Other Gand A | $7,245,000 | $8,274,000 | $7,184,000 | $7,794,000 |
| Salaries And Wages | $446,000 | $1,370,000 | $1,904,000 | $1,837,000 |
| Gain On Sale Of Security | - | $12,000 | $29,000 | - |
Fetched: 2026-06-12
Balance Sheet (Annual)
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $10,492,000 | $3,601,000 | $15,329,000 | $30,209,000 |
| Total Assets | $14,650,000 | $6,349,000 | $20,313,000 | $33,296,000 |
| Total Non Current Assets | $2,519,000 | $2,413,000 | $3,265,000 | $3,763,000 |
| Other Non Current Assets | $1,233,000 | $445,000 | $658,000 | $948,000 |
| Current Assets | $12,131,000 | $3,936,000 | $17,048,000 | $29,533,000 |
| Other Current Assets | $12,000 | $4,000 | $69,000 | $858,000 |
| Prepaid Assets | $777,000 | $701,000 | $820,000 | $858,000 |
| Inventory | $0 | $297,000 | $0 | - |
| Receivables | $30,000 | $33,000 | $152,000 | $0 |
| Accounts Receivable | $30,000 | $33,000 | $152,000 | $0 |
| Cash Cash Equivalents And Short Term Investments | $11,312,000 | $2,901,000 | $16,007,000 | $28,675,000 |
| Cash And Cash Equivalents | $11,312,000 | $2,901,000 | $15,301,000 | $28,675,000 |
| Non Current Prepaid Assets | - | - | - | $805,000 |
| Debt | ||||
| Total Debt | $942,000 | $1,394,000 | $1,805,000 | $2,183,000 |
| Long Term Debt And Capital Lease Obligation | $421,000 | $888,000 | $1,313,000 | $1,704,000 |
| Current Debt And Capital Lease Obligation | $521,000 | $506,000 | $492,000 | $479,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $4,158,000 | $2,748,000 | $4,984,000 | $3,087,000 |
| Total Non Current Liabilities Net Minority Interest | $421,000 | $888,000 | $1,313,000 | $1,704,000 |
| Current Liabilities | $3,737,000 | $1,860,000 | $3,671,000 | $1,383,000 |
| Other Current Liabilities | $346,000 | - | - | - |
| Payables And Accrued Expenses | $2,218,000 | $818,000 | $2,570,000 | $470,000 |
| Payables | $1,644,000 | $627,000 | $331,000 | $415,000 |
| Accounts Payable | $1,644,000 | $627,000 | $331,000 | $415,000 |
| Equity | ||||
| Common Stock Equity | $10,492,000 | $3,601,000 | $15,329,000 | $30,209,000 |
| Total Equity Gross Minority Interest | $10,492,000 | $3,601,000 | $15,329,000 | $30,209,000 |
| Stockholders Equity | $10,492,000 | $3,601,000 | $15,329,000 | $30,209,000 |
| Retained Earnings | $-342,157,000 | $-339,669,000 | $-324,998,000 | $-307,739,000 |
| Gains Losses Not Affecting Retained Earnings | - | $0 | $2,000 | $0 |
| Other Equity Adjustments | - | - | $2,000 | - |
| Other | ||||
| Treasury Shares Number | $3 | $3 | $3 | $3 |
| Ordinary Shares Number | $1,898,065 | $839,810 | $726,408 | $725,885 |
| Share Issued | $1,898,068 | $839,813 | $726,411 | $725,888 |
| Tangible Book Value | $10,492,000 | $3,601,000 | $15,329,000 | $30,209,000 |
| Invested Capital | $10,492,000 | $3,601,000 | $15,329,000 | $30,209,000 |
| Working Capital | $8,394,000 | $2,076,000 | $13,377,000 | $28,150,000 |
| Capital Lease Obligations | $942,000 | $1,394,000 | $1,805,000 | $2,183,000 |
| Total Capitalization | $10,492,000 | $3,601,000 | $15,329,000 | $30,209,000 |
| Treasury Stock | $1,000 | $1,000 | $1,000 | $1,000 |
| Additional Paid In Capital | $352,648,000 | $343,270,000 | $340,317,000 | $337,940,000 |
| Capital Stock | $2,000 | $1,000 | $9,000 | $9,000 |
| Common Stock | $2,000 | $1,000 | $9,000 | $9,000 |
| Long Term Capital Lease Obligation | $421,000 | $888,000 | $1,313,000 | $1,704,000 |
| Current Capital Lease Obligation | $521,000 | $506,000 | $492,000 | $479,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $652,000 | $536,000 | $609,000 | $434,000 |
| Current Accrued Expenses | $574,000 | $191,000 | $2,239,000 | $55,000 |
| Net PPE | $1,286,000 | $1,968,000 | $2,607,000 | $2,815,000 |
| Accumulated Depreciation | $-1,521,000 | $-1,258,000 | $-1,276,000 | $-1,071,000 |
| Gross PPE | $2,807,000 | $3,226,000 | $3,883,000 | $3,886,000 |
| Other Properties | $1,630,000 | $1,617,000 | $1,575,000 | $1,171,000 |
| Machinery Furniture Equipment | $310,000 | $310,000 | $603,000 | $562,000 |
| Buildings And Improvements | $867,000 | $1,299,000 | $1,705,000 | $2,153,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $0 | $297,000 | $0 | - |
| Other Short Term Investments | - | $0 | $706,000 | $0 |
Fetched: 2026-06-12
Cash Flow Statement (Annual)
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-9,474,000 | $-14,695,000 | $-12,804,000 | $-8,862,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-9,461,000 | $-14,653,000 | $-12,408,000 | $-8,453,000 |
| Cash Flow From Continuing Operating Activities | $-9,461,000 | $-14,653,000 | $-12,408,000 | $-8,453,000 |
| Operating Gains Losses | $-10,000,000 | $-12,000 | $-20,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-13,000 | $-42,000 | $-396,000 | $-409,000 |
| Investing Cash Flow | $9,025,000 | $816,000 | $-966,000 | $-409,000 |
| Cash Flow From Continuing Investing Activities | $9,025,000 | $816,000 | $-966,000 | $-409,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $8,847,000 | $1,437,000 | $0 | $251,000 |
| Financing Cash Flow | $8,847,000 | $1,437,000 | $0 | $205,000 |
| Cash Flow From Continuing Financing Activities | $8,847,000 | $1,437,000 | $0 | $205,000 |
| Net Common Stock Issuance | $8,847,000 | $1,437,000 | $0 | $251,000 |
| Common Stock Issuance | $8,847,000 | $1,437,000 | $0 | $251,000 |
| Repurchase Of Capital Stock | - | - | - | $0 |
| Net Other Financing Charges | - | - | - | $-46,000 |
| Other | ||||
| Interest Paid Supplemental Data | $10,000 | $0 | - | - |
| Income Tax Paid Supplemental Data | $2,000 | $2,000 | $2,000 | $2,000 |
| End Cash Position | $11,455,000 | $3,044,000 | $15,444,000 | $28,818,000 |
| Beginning Cash Position | $3,044,000 | $15,444,000 | $28,818,000 | $37,475,000 |
| Changes In Cash | $8,411,000 | $-12,400,000 | $-13,374,000 | $-8,657,000 |
| Net Investment Purchase And Sale | $38,000 | $858,000 | $-570,000 | $0 |
| Sale Of Investment | $3,000,000 | $11,718,000 | $10,384,000 | $0 |
| Purchase Of Investment | $-2,962,000 | $-10,860,000 | $-10,954,000 | $0 |
| Net PPE Purchase And Sale | $8,987,000 | $-42,000 | $-396,000 | $-409,000 |
| Sale Of PPE | $9,000,000 | $0 | - | $0 |
| Purchase Of PPE | $-13,000 | $-42,000 | $-396,000 | $-409,000 |
| Change In Working Capital | $1,037,000 | $-2,022,000 | $2,306,000 | $597,000 |
| Change In Other Current Liabilities | $-452,000 | $-411,000 | - | - |
| Change In Payables And Accrued Expense | $1,734,000 | $-1,825,000 | $2,211,000 | $183,000 |
| Change In Accrued Expense | $717,000 | $-2,121,000 | $2,359,000 | $49,000 |
| Change In Payable | $1,017,000 | $296,000 | $-148,000 | $134,000 |
| Change In Account Payable | $1,017,000 | $296,000 | $-148,000 | $134,000 |
| Change In Prepaid Assets | $253,000 | $392,000 | $177,000 | $384,000 |
| Change In Inventory | $-501,000 | $-297,000 | $0 | - |
| Change In Receivables | $3,000 | $119,000 | $-152,000 | $0 |
| Changes In Account Receivables | $3,000 | $119,000 | $-152,000 | $0 |
| Other Non Cash Items | $432,000 | $406,000 | - | - |
| Stock Based Compensation | $532,000 | $1,508,000 | $2,377,000 | $2,256,000 |
| Asset Impairment Charge | $798,000 | $0 | - | - |
| Amortization Of Securities | $-38,000 | $-142,000 | $-105,000 | $0 |
| Depreciation Amortization Depletion | $266,000 | $280,000 | $293,000 | $142,000 |
| Depreciation And Amortization | $266,000 | $280,000 | $293,000 | $142,000 |
| Earnings Losses From Equity Investments | $0 | $-12,000 | $-29,000 | $0 |
| Net Income From Continuing Operations | $-2,488,000 | $-14,671,000 | $-17,259,000 | $-11,448,000 |
| Change In Other Working Capital | - | $-5,000 | $70,000 | $30,000 |
| Gain Loss On Sale Of PPE | - | $0 | $9,000 | $0 |
| Proceeds From Stock Option Exercised | - | - | - | $0 |
| Common Stock Payments | - | - | - | $0 |
Fetched: 2026-06-12